Top

Published in:

Open Access 01-07-2017

PET-CMR in heart failure - synergistic or redundant imaging?

Authors: Michael A. Quail, Albert J. Sinusas

Published in: Heart Failure Reviews | Issue 4/2017

Abstract

Imaging in heart failure (HF) provides data for diagnosis, prognosis and disease monitoring. Both MRI and nuclear imaging techniques have been successfully used for this purpose in HF. Positron Emission Tomography-Cardiac Magnetic Resonance (PET-CMR) is an example of a new multimodality diagnostic imaging technique with potential applications in HF. The threshold for adopting a new diagnostic tool to clinical practice must necessarily be high, lest they exacerbate costs without improving care. New modalities must demonstrate clinical superiority, or at least equivalence, combined with another important advantage, such as lower cost or improved patient safety. The purpose of this review is to outline the current status of multimodality PET-CMR with regard to HF applications, and determine whether the clinical utility of this new technology justifies the cost.

Cook C, Cole G, Asaria P, Jabbour R, Francis DP (2014) The annual global economic burden of heart failure. Int J Cardiol 171(3):368–376. doi:10.1016/j.ijcard.2013.12.028 CrossRefPubMed

Bailey DL, Pichler BJ, Guckel B, Barthel H, Beer AJ, Botnar R, Gillies R, Goh V, Gotthardt M, Hicks RJ, Lanzenberger R, la Fougere C, Lentschig M, Nekolla SG, Niederdraenk T, Nikolaou K, Nuyts J, Olego D, Riklund KA, Signore A, Schafers M, Sossi V, Suminski M, Veit-Haibach P, Umutlu L, Wissmeyer M, Beyer T (2016) Combined PET/MRI: from status quo to status go. Summary report of the fifth international workshop on PET/MR imaging; February 15-19, 2016; Tubingen, Germany. Mol Imaging Biol 18(5):637–650. doi:10.1007/s11307-016-0993-2 CrossRefPubMedPubMedCentral

Bart BA, Shaw LK, McCants CB Jr, Fortin DF, Lee KL, Califf RM, O'Connor CM (1997) Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 30(4):1002–1008CrossRefPubMed

Petibon Y, Guehl NJ, Reese TG, Ebrahimi B, Normandin MD, Shoup TM, Alpert NM, El Fakhri G, Ouyang J (2016) Impact of motion and partial volume effects correction on PET myocardial perfusion imaging using simultaneous PET-MR. Phys Med Biol 62(2):326CrossRefPubMedPubMedCentral

Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Gropler RJ (2009) ASNC imaging guidelines for nuclear cardiology procedures: PET myocardial perfusion and metabolism clinical imaging. J Nucl Cardiol 16(4):651CrossRef

Sinusas AJ (2010) Molecular imaging in nuclear cardiology: translating research concepts into clinical applications. Q J Nucl Med Mol Imaging 54(2):230–240PubMed

Schindler TH, Schelbert HR, Quercioli A, Dilsizian V (2010) Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. J Am Coll Cardiol Img 3(6):623–640. doi:10.1016/j.jcmg.2010.04.007 CrossRef

Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG (1994) Relation between myocardial blood flow and the severity of coronary-artery stenosis. New Engl J Med 330(25):1782–1788CrossRefPubMed

Ziadi MC, Williams KA, Guo A, Chow BJ, Renaud JM, Ruddy TD, Sarveswaran N, Tee RE, Beanlands RS (2011) Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol 58(7):740–748CrossRefPubMed

10.

Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM, Burkhard N, Wyss CA, Kaufmann PA (2009) Long-term prognostic value of 13 N-ammonia myocardial perfusion positron emission tomography: added value of coronary flow reserve. J Am Coll Cardiol 54(2):150–156CrossRefPubMed

11.

Steeden JA, Knight DS, Bali S, Atkinson D, Taylor AM, Muthurangu V (2014) Self-navigated tissue phase mapping using a golden-angle spiral acquisition-proof of concept in patients with pulmonary hypertension. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 71(1):145–155. doi:10.1002/mrm.24646 CrossRef

12.

Budge LP, Helms AS, Salerno M, Kramer CM, Epstein FH, Bilchick KC (2012) MR cine DENSE dyssynchrony parameters for the evaluation of heart failure: comparison with myocardial tissue tagging. JACC Cardiovasc Imaging 5(8):789–797. doi:10.1016/j.jcmg.2011.12.024 CrossRefPubMedPubMedCentral

13.

Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ (2000) Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2(4):271–278CrossRefPubMed

14.

Morton G, Chiribiri A, Ishida M, Hussain ST, Schuster A, Indermuehle A, Perera D, Knuuti J, Baker S, Hedström E, Schleyer P, O'Doherty M, Barrington S, Nagel E (2012) Quantification of absolute myocardial perfusion in patients with coronary artery disease: comparison between cardiovascular magnetic resonance and positron emission tomography. J Am Coll Cardiol 60(16):1546–1555. doi:10.1016/j.jacc.2012.05.052 CrossRefPubMed

15.

Christian TF, Rettmann DW, Aletras AH, Liao SL, Taylor JL, Balaban RS, Arai AE (2004) Absolute myocardial perfusion in canines measured by using dual-bolus first-pass MR imaging 1. Radiology 232(3):677–684CrossRefPubMed

16.

Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS (2002) Long-term trends in the incidence of and survival with heart failure. New Engl J Med 347(18):1397–1402CrossRefPubMed

17.

Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. New Engl J Med 351(20):2049–2057CrossRefPubMed

18.

Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT (2011) Coronary-artery bypass surgery in patients with left ventricular dysfunction. New Engl J Med 364(17):1607–1616CrossRefPubMedPubMedCentral

19.

Doshi D, Ben-Yehuda O, Bonafede M, Josephy N, Karmpaliotis D, Parikh MA, Moses JW, Stone GW, Leon MB, Schwartz A, Kirtane AJ (2016) Underutilization of coronary artery disease testing among patients hospitalized with new-onset heart failure. J Am Coll Cardiol 68(5):450–458. doi:10.1016/j.jacc.2016.05.060 CrossRefPubMed

20.

Parker MW, Iskandar A, Limone B, Perugini A, Kim H, Jones C, Calamari B, Coleman CI, Heller GV (2012) Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: a bivariate meta-analysis. Circulation: Cardiovascular Imaging 5(6):700–707. doi:10.1161/CIRCIMAGING.112.978270

21.

Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS (2003) Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 107(23):2900–2907CrossRefPubMed

22.

Lau J, Laforest R, Zheng J, Lesniak D, Priatna A, Gropler R, Woodard P (2014) 13N-ammonia PET/MR myocardial stress perfusion imaging early experience. J Nucl Med 55(supplement 1):242–242

23.

Durrani A, Lau J, Laforest R, Zheng J, Lesniak D, Priatna A, Gropler R, Woodard P (2016) 13N–ammonia PET/MR myocardial stress perfusion imaging early experience. In: Radiological Society of North America 2015 Scientific Assembly and Annual Meeting. http://archive.rsna.org/2015/15012463.html

24.

Lipinski MJ, McVey CM, Berger JS, Kramer CM, Salerno M (2013) Prognostic value of stress cardiac magnetic resonance imaging in patients with known or suspected coronary artery disease: a systematic review and meta-analysis. J Am Coll Cardiol 62(9):826–838. doi:10.1016/j.jacc.2013.03.080 CrossRefPubMed

25.

Gargiulo P, Dellegrottaglie S, Bruzzese D, Savarese G, Scala O, Ruggiero D, D'Amore C, Paolillo S, Agostoni P, Bossone E, Soricelli A, Cuocolo A, Trimarco B, Perrone Filardi P (2013) The prognostic value of normal stress cardiac magnetic resonance in patients with known or suspected coronary artery disease: a meta-analysis. Circ Cardiovasc Imaging 6(4):574–582. doi:10.1161/circimaging.113.000035 CrossRefPubMed

26.

Allman KC, Shaw LJ, Hachamovitch R, Udelson JE (2002) Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 39(7):1151–1158CrossRefPubMed

27.

Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N, Freeman M, Gulenchyn KY, Garrard L, deKemp R, Guo A, Ruddy TD, Benard F, Lamy A, Iwanochko RM (2007) F-18-fluorodeoxyglucose positron emission tomography imaging-assisted Management of Patients with Severe Left Ventricular Dysfunction and Suspected Coronary Disease. A randomized, controlled trial (PARR-2). J Am Coll Cardiol 50(20):2002–2012. doi:10.1016/j.jacc.2007.09.006 CrossRefPubMed

28.

D'Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, Ruddy TD, DaSilva J, Humen D, Gulenchyn KY, Freeman M, Racine N, Benard F, Hendry P, Beanlands RSB (2009) Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. J Am Coll Cardiol Img 2(9):1060–1068. doi:10.1016/j.jcmg.2009.02.017 CrossRef

29.

Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T (2011) Myocardial viability and survival in ischemic left ventricular dysfunction. New Engl J Med 364(17):1617–1625CrossRefPubMedPubMedCentral

30.

Srichai MB, Jaber WA (2013) Viability by MRI or PET would have changed the results of the STICH trial. Prog Cardiovasc Dis 55(5):487–493CrossRefPubMed

31.

Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, Hachamovitch R (2013) Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction inducible ischemia versus hibernating myocardium. Circulation: Cardiovascular Imaging 6(3):363–372

32.

Kim RJ, Wu E, Rafael A, Chen E-L, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. New Engl J Med 343(20):1445–1453CrossRefPubMed

33.

Klein C, Nekolla SG, Bengel FM, Momose M, Sammer A, Haas F, Schnackenburg B, Delius W, Mudra H, Wolfram D (2002) Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging comparison with positron emission tomography. Circulation 105(2):162–167CrossRef

34.

Beanlands RS, Ruddy TD, Iwanochko RM, Coates G, Freeman M, Nahmias C, Hendry P, Burns RJ, Lamy A, Mickleborough L (2002) Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 40(10):1735–1743CrossRefPubMed

35.

Romero J, Xue X, Gonzalez W, Garcia MJ (2012) CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: a meta-analysis of prospective trials. J Am Coll Cardiol Img 5(5):494–508. doi:10.1016/j.jcmg.2012.02.009 CrossRef

36.

Bulluck H, White SK, Frohlich GM, Casson SG, O'Meara C, Newton A, Nicholas J, Weale P, Wan SM, Sirker A, Moon JC, Yellon DM, Groves A, Menezes L, Hausenloy DJ (2016) Quantifying the area at risk in reperfused ST-segment-elevation myocardial infarction patients using hybrid cardiac positron emission tomography-magnetic resonance imaging. Circ Cardiovasc Imaging 9(3):e003900. doi:10.1161/CIRCIMAGING.115.003900 CrossRefPubMedPubMedCentral

37.

Rischpler C, Langwieser N, Souvatzoglou M, Batrice A, van Marwick S, Snajberk J, Ibrahim T, Laugwitz KL, Nekolla SG, Schwaiger M (2015) PET/MRI early after myocardial infarction: evaluation of viability with late gadolinium enhancement transmurality vs. 18F-FDG uptake. Eur Heart J Cardiovasc Imaging 16(6):661–669. doi:10.1093/ehjci/jeu317 PubMed

38.

Robson PM, Dweck MR, Trivieri MG, Abgral R, Karakatsanis NA, Contreras J, Gidwani U, Narula JP, Fuster V, Kovacic JC, Fayad ZA (2017) Coronary artery PET/MR imaging. Feasibility, Limitations, and Solutions. doi:10.1016/j.jcmg.2016.09.029

39.

Hamzeh N, Steckman DA, Sauer WH, Judson MA (2015) Pathophysiology and clinical management of cardiac sarcoidosis. Nat Rev Cardiol 12(5):278–288. doi:10.1038/nrcardio.2015.22 CrossRefPubMed

40.

Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, Crijns HJ (2005) Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest 128(1):30–35. doi:10.1378/chest.128.1.30 CrossRefPubMed

41.

Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ (2009) Detection of myocardial damage in patients with sarcoidosis. Circulation 120(20):1969–1977. doi:10.1161/CIRCULATIONAHA.109.851352 CrossRefPubMedPubMedCentral

42.

Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, Ito N, Ohira H, Ikeda D, Tamaki N, Nishimura M (2005) Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 26(15):1538–1543. doi:10.1093/eurheartj/ehi180 CrossRefPubMed

43.

Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, Miura M, Sakaue S, Tamaki N, Nishimura M (2008) Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 35(5):933–941. doi:10.1007/s00259-007-0650-8 CrossRefPubMed

44.

O'Meara C, Menezes LJ, White SK, Wicks E, Elliott P (2013) Inital experience of imaging cardiac sarcoidosis using hybrid PET-MR - a technologist's case study. J Cardiovasc Magn Reson 15(1):T1. doi:10.1186/1532-429x-15-s1-t1 CrossRefPubMedCentral

45.

Schneider S, Batrice A, Rischpler C, Eiber M, Ibrahim T, Nekolla SG (2014) Utility of multimodal cardiac imaging with PET/MRI in cardiac sarcoidosis: implications for diagnosis, monitoring and treatment. Eur Heart J 35(5):312–312. doi:10.1093/eurheartj/eht335 CrossRefPubMed

46.

Wada K, Niitsuma T, Yamaki T, Masuda A, Ito H, Kubo H, Hara T, Takenoshita S, Takeishi Y (2016) Simultaneous cardiac imaging to detect inflammation and scar tissue with (18)F-fluorodeoxyglucose PET/MRI in cardiac sarcoidosis. J Nucl Cardiol 23(5):1180–1182. doi:10.1007/s12350-015-0348-4 CrossRefPubMed

47.

Abgral R, Dweck MR, Trivieri MG, Robson PM, Karakatsanis N, Mani V, Padilla M, Miller M, Lala A, Sanz J, Narula J, Fuster V, Contreras J, Kovacic JC, Fayad ZA (2016) Clinical utility of combined FDG-PET/MR to assess myocardial disease. J Am Coll Cardiol Img. doi:10.1016/j.jcmg.2016.02.029

48.

Coulden R, Jones H, Sonnex E, Das I, Abele J (2014) Cardiac MRI and FDG-PET in the diagnosis of cardiac sarcoidosis. J Cardiovasc Magn Reson 16(1):P299. doi:10.1186/1532-429x-16-s1-p299 CrossRefPubMedCentral

49.

Galati G, Leone O, Rapezzi C (2014) The difficult diagnosis of isolated cardiac sarcoidosis: usefulness of an integrated MRI and PET approach. Heart 100(1):89–90. doi:10.1136/heartjnl-2013-304237 CrossRefPubMed

50.

Law WP, Wang WY, Moore PT, Mollee PN, Ng AC (2016) Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 57(11):1733–1739. doi:10.2967/jnumed.115.169870 CrossRef

51.

Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H (2015) Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation:CIRCULATIONAHA. 115:016567

52.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M (2016) Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation:CIRCULATIONAHA 116:021612

53.

Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, Longhi S, Lorenzini M, Reggiani LB, Gagliardi C, Gallo P, Villani C, Salvi F (2011) Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. J Am Coll Cardiol Img 4(6):659–670. doi:10.1016/j.jcmg.2011.03.016 CrossRef

54.

Trivieri MG, Dweck MR, Abgral R, Robson PM, Karakatsanis NA, Lala A, Contreras J, Sahni G, Gopalan R, Gorevic P, Fuster V, Narula J, Fayad ZA (2016) 18F-sodium fluoride PET/MR for the assessment of cardiac amyloidosis. J Am Coll Cardiol 68(24):2712–2714. doi:10.1016/j.jacc.2016.09.953 CrossRefPubMedPubMedCentral

55.

Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P (2008) Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 216(2):253–261. doi:10.1002/path.2411 CrossRefPubMed

56.

Pilebro B, Arvidsson S, Lindqvist P, Sundstrom T, Westermark P, Antoni G, Suhr O, Sorensen J (2016) Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J Nucl Cardiol. doi:10.1007/s12350-016-0638-5 PubMed

57.

Lurz P, Eitel I, Adam J, Steiner J, Grothoff M, Desch S, Fuernau G, de Waha S, Sareban M, Luecke C (2012) Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. J Am Coll Cardiol Img 5(5):513–524CrossRef

58.

Lurz P, Luecke C, Eitel I, Fohrenbach F, Frank C, Grothoff M, de Waha S, Rommel KP, Lurz JA, Klingel K, Kandolf R, Schuler G, Thiele H, Gutberlet M (2016) Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the MyoRacer-trial. J Am Coll Cardiol 67(15):1800–1811. doi:10.1016/j.jacc.2016.02.013 CrossRefPubMed

59.

Nensa F, Poeppel TD, Krings P, Schlosser T (2014) Multiparametric assessment of myocarditis using simultaneous positron emission tomography/magnetic resonance imaging. Eur Heart J 35(32):2173–2173. doi:10.1093/eurheartj/ehu086 CrossRefPubMed

60.

Gambarin FI, Disabella E, Narula J, Diegoli M, Grasso M, Serio A, Favalli BM, Agozzino M, Tavazzi L, Fraser AG, Arbustini E (2010) When should cardiologists suspect Anderson-fabry disease? Am J Cardiol 106(10):1492–1499. doi:10.1016/j.amjcard.2010.07.016 CrossRefPubMed

61.

Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, Strotmann J, Tallaj J, Tran TC, West ML, Beitner-Johnson D, Abiose A (2011) Cardiovascular events in patients with fabry disease natural history data from the fabry registry. J Am Coll Cardiol 57(9):1093–1099. doi:10.1016/j.jacc.2010.11.018 CrossRefPubMed

62.

Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, Marmo M, Liuzzi R, Visciano B, Cianciaruso B, Salvatore M (2009) Effects of enzyme-replacement therapy in patients with Anderson-fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart 95(13):1103–1107. doi:10.1136/hrt.2008.162800 CrossRefPubMed

63.

Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW (2009) Cardiac microvascular pathology in fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 119(19):2561–2567. doi:10.1161/circulationaha.108.841494 CrossRefPubMed

64.

Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, Voelker W, Ertl G, Wanner C, Strotmann J (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119(4):524–529. doi:10.1161/circulationaha.108.794529 CrossRefPubMed

65.

Nappi C, Altiero M, Imbriaco M, Nicolai E, Giudice CA, Aiello M, Diomiaiuti CT, Pisani A, Spinelli L, Cuocolo A (2015) First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-fabry disease. Eur J Nucl Med Mol Imaging 42(7):1025–1031. doi:10.1007/s00259-015-3036-3 CrossRefPubMed

66.

Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J (2010) Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView myocardial imaging for risk evaluation in heart failure) study. J Am Coll Cardiol 55(20):2212–2221CrossRefPubMed

67.

Hartmann F, Ziegler S, Nekolla S, Hadamitzky M, Seyfarth M, Richardt G, Schwaiger M (1999) Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: an analysis using carbon-11 hydroxyephedrine and positron emission tomography. Heart 81(3):262–270CrossRefPubMedPubMedCentral

68.

Matsunari I, Aoki H, Nomura Y, Takeda N, Chen W-P, Taki J, Nakajima K, Nekolla SG, Kinuya S, Kajinami K (2010) Iodine-123 Metaiodobenzylguanidine imaging and carbon-11 hydroxyephedrine positron emission tomography compared in patients with left ventricular DysfunctionClinical perspective. Circulation: Cardiovascular Imaging 3(5):595–603

69.

Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldwa S, Mashtare TL Jr, Hutson AD, deKemp RA, Haka MS, Sajjad M, Cimato TR, Curtis AB, Cain ME, Canty JM Jr (2014) Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 63(2):141–149. doi:10.1016/j.jacc.2013.07.096 CrossRefPubMed

70.

de Haan S, Rijnierse MT, Harms HJ, Verberne HJ, Lammertsma AA, Huisman MC, Windhorst AD, van Rossum AC, Allaart CP, Knaapen P (2016) Myocardial denervation coincides with scar heterogeneity in ischemic cardiomyopathy: a PET and CMR study. J Nucl Cardiol 23(6):1480–1488. doi:10.1007/s12350-015-0316-z CrossRefPubMed

71.

Sinusas AJ, Lazewatsky J, Brunetti J, Heller G, Srivastava A, Liu YH, Sparks R, Puretskiy A, Lin SF, Crane P, Carson RE, Lee LV (2014) Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 55(9):1445–1451. doi:10.2967/jnumed.114.140137 CrossRef

72.

Thackeray JT, Bengel FM (2013) Assessment of cardiac autonomic neuronal function using PET imaging. J Nucl Cardiol 20(1):150–165. doi:10.1007/s12350-012-9644-4 CrossRefPubMed

73.

Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK (2001) An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive heart failure. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 42(1):55–62

74.

Schroeder MA, Lau AZ, Chen AP, Gu Y, Nagendran J, Barry J, Hu X, Dyck JR, Tyler DJ, Clarke K (2013) Hyperpolarized 13C magnetic resonance reveals early-and late-onset changes to in vivo pyruvate metabolism in the failing heart. Eur J Heart Fail 15(2):130–140CrossRefPubMed

75.

Korngold EC, Jaffer FA, Weissleder R, Sosnovik DE (2008) Noninvasive imaging of apoptosis in cardiovascular disease. Heart Fail Rev 13(2):163–173. doi:10.1007/s10741-007-9068-4 CrossRefPubMedPubMedCentral

76.

Kietselaer BL, Reutelingsperger CP, Boersma HH, Heidendal GA, Liem H, Crijns HJ, Narula J, Hofstra L (2007) Noninvasive detection of programmed cell loss with 99mTc-labeled annexin A5 in heart failure. J Nucl Med 48(4):562–567CrossRefPubMed

77.

Grierson JR, Yagle KJ, Eary JF, Tait JF, Gibson DF, Lewellen B, Link JM, Krohn KA (2004) Production of [F-18] fluoroannexin for imaging apoptosis with PET. Bioconjug Chem 15(2):373–379CrossRefPubMed

78.

Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Dai G, Reynolds F, Grazette L, Rosenzweig A, Weissleder R, Josephson L (2005) Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 54(3):718–724. doi:10.1002/mrm.20617 CrossRef

79.

Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ 3rd, Spinale FG, Gold MR (2006) Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 97(4):532–537. doi:10.1016/j.amjcard.2005.08.073 CrossRefPubMed

80.

Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Arfanakis DA, Maliaraki NE, Lathourakis CE, Chlouverakis GI, Vardas PE (2008) Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. J Am Coll Cardiol 52(3):211–215. doi:10.1016/j.jacc.2008.03.045 CrossRefPubMed

81.

Sahul ZH, Mukherjee R, Song J, McAteer J, Stroud RE, Dione DP, Staib L, Papademetris X, Dobrucki LW, Duncan JS, Spinale FG, Sinusas AJ (2011) Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging 4(4):381–391. doi:10.1161/circimaging.110.961854 CrossRefPubMedPubMedCentral

82.

Jenkins WS, Vesey AT, Stirrat C, Connell M, Lucatelli C, Neale A, Moles C, Vickers A, Fletcher A, Pawade T, Wilson I, Rudd JH, van Beek EJ, Mirsadraee S, Dweck MR, Newby DE (2016) Cardiac alphaVbeta3 integrin expression following acute myocardial infarction in humans. Heart. doi:10.1136/heartjnl-2016-310115 PubMed

83.

Martinez-Moller A, Souvatzoglou M, Delso G, Bundschuh RA, Chefd'hotel C, Ziegler SI, Navab N, Schwaiger M, Nekolla SG (2009) Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 50(4):520–526. doi:10.2967/jnumed.108.054726 CrossRef

84.

Yoo HJ, Lee JS, Lee JM (2015) Integrated whole body MR/PET: where are We? Korean J Radiol 16(1):32–49. doi:10.3348/kjr.2015.16.1.32 CrossRefPubMedPubMedCentral

Title: PET-CMR in heart failure - synergistic or redundant imaging?
Authors: Michael A. Quail
Albert J. Sinusas
Publication date: 01-07-2017
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 4/2017
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-017-9607-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

PET-CMR in heart failure - synergistic or redundant imaging?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Cardiac magnetic resonance imaging in heart failure: where the alphabet begins!

Strain imaging using cardiac magnetic resonance

Assessment of myocardial blood flow and coronary flow reserve with positron emission tomography in ischemic heart disease: current state and future directions

T2 mapping and T2* imaging in heart failure

Introduction to the Special Issue: Myocardial Imaging in Heart Failure

Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page